{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:38:45Z","timestamp":1791506325738,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017949","name":"Health Commission of Shanxi Province","doi-asserted-by":"publisher","award":["no.2019034"],"award-info":[{"award-number":["no.2019034"]}],"id":[{"id":"10.13039\/100017949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018611","name":"International Science and Technology Cooperation Program of Shanxi Province","doi-asserted-by":"publisher","award":["20210302123245"],"award-info":[{"award-number":["20210302123245"]}],"id":[{"id":"10.13039\/501100018611","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00415-024-12321-4","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T18:01:33Z","timestamp":1711476093000},"page":"3506-3511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Efgartigimod in the treatment of Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1007","volume":"271","author":[{"given":"Huiqiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-5599","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"10280","key":"12321_CR1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/s0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barr\u00e9 syndrome. Lancet (London, England) 397(10280):1214\u20131228. https:\/\/doi.org\/10.1016\/s0140-6736(21)00517-1","journal-title":"Lancet (London, England)"},{"issue":"31","key":"12321_CR2","doi-asserted-by":"publisher","first-page":"11404","DOI":"10.1073\/pnas.0402391101","volume":"101","author":"N Yuki","year":"2004","unstructured":"Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K et al (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 101(31):11404\u201311409. https:\/\/doi.org\/10.1073\/pnas.0402391101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"12321_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ana.410380214","volume":"38","author":"I Illa","year":"1995","unstructured":"Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC (1995) Acute axonal Guillain-Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 38(2):218\u2013224. https:\/\/doi.org\/10.1002\/ana.410380214","journal-title":"Ann Neurol"},{"issue":"8","key":"12321_CR4","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1007\/s00415-015-7806-4","volume":"262","author":"M Koga","year":"2015","unstructured":"Koga M, Takahashi M, Yokoyama K, Kanda T (2015) Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barr\u00e9 syndrome and its variants. J Neurol 262(8):1954\u20131960. https:\/\/doi.org\/10.1007\/s00415-015-7806-4","journal-title":"J Neurol"},{"key":"12321_CR5","doi-asserted-by":"crossref","unstructured":"(1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma exchange\/sandoglobulin Guillain-Barr\u00e9 syndrome trial group. Lancet (London, England). 349(9047):225\u201330.","DOI":"10.1016\/S0140-6736(96)09095-2"},{"issue":"5","key":"12321_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"Donofrio PD, Berger A, Brannagan TH 3rd, Bromberg MB, Howard JF, Latov N et al (2009) Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40(5):890\u2013900. https:\/\/doi.org\/10.1002\/mus.21433","journal-title":"Muscle Nerve"},{"issue":"3","key":"12321_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11940-020-0616-8","volume":"22","author":"A Patel","year":"2020","unstructured":"Patel A, Lynch F, Shepherd SA (2020) Newer immunotherapies for the treatment of acute neuromuscular disease in the critical care unit. Curr Treat Options Neurol 22(3):7. https:\/\/doi.org\/10.1007\/s11940-020-0616-8","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"12321_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/cnd.0000000000000235","volume":"20","author":"AZ Burakgazi","year":"2019","unstructured":"Burakgazi AZ (2019) Immunoglobulin treatment in neuromuscular medicine. J Clin Neuromuscul Dis 20(4):182\u2013193. https:\/\/doi.org\/10.1097\/cnd.0000000000000235","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"12321_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5603\/ait.2013.0002","volume":"45","author":"W Szczeklik","year":"2013","unstructured":"Szczeklik W, Wawrzycka K, W\u0142udarczyk A, Sega A, Nowak I, Seczy\u0144ska B et al (2013) Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensiv Ther 45(1):7\u201313. https:\/\/doi.org\/10.5603\/ait.2013.0002","journal-title":"Anaesthesiol Intensiv Ther"},{"issue":"4","key":"12321_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s1474-4422(20)30494-4","volume":"20","author":"C Walgaard","year":"2021","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY et al (2021) Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20(4):275\u2013283. https:\/\/doi.org\/10.1016\/s1474-4422(20)30494-4","journal-title":"Lancet Neurol"},{"issue":"9","key":"12321_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"12321_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, S\u00e1nchez-Gonz\u00e1lez B, Rejt\u0151 L, Egyed M, Romanyuk N, Godar M et al (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95(2):178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680","journal-title":"Am J Hematol"},{"issue":"10","key":"12321_CR13","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/jci97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig 128(10):4372\u20134386. https:\/\/doi.org\/10.1172\/jci97911","journal-title":"J Clin Investig"},{"issue":"23","key":"12321_CR14","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/wnl.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661\u2013e2673. https:\/\/doi.org\/10.1212\/wnl.0000000000007600","journal-title":"Neurology"},{"issue":"7","key":"12321_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"12","key":"12321_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/1744666x.2022.2136167","volume":"18","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Uzawa A, Murai H (2022) Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Expert Rev Clin Immunol 18(12):1207\u20131215. https:\/\/doi.org\/10.1080\/1744666x.2022.2136167","journal-title":"Expert Rev Clin Immunol"},{"issue":"10413","key":"12321_CR17","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/s0140-6736(23)01460-5","volume":"402","author":"CM Broome","year":"2023","unstructured":"Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H et al (2023) Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England) 402(10413):1648\u20131659. https:\/\/doi.org\/10.1016\/s0140-6736(23)01460-5","journal-title":"Lancet (London, England)"},{"issue":"3","key":"12321_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Cs\u00f6rg\u0151 Z, De Simone C, Didona B, Remenyik E, Reznichenko N et al (2022) Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 186(3):429\u2013439. https:\/\/doi.org\/10.1111\/bjd.20782","journal-title":"Br J Dermatol"},{"issue":"6","key":"12321_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K et al (2018) Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17(6):519\u2013529. https:\/\/doi.org\/10.1016\/s1474-4422(18)30114-5","journal-title":"Lancet Neurol"},{"issue":"2","key":"12321_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mus.24207","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner A, Barnett C, Bril V (2014) INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 50(2):164\u2013169. https:\/\/doi.org\/10.1002\/mus.24207","journal-title":"Muscle Nerve"},{"issue":"1","key":"12321_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2456","volume":"12","author":"K Ren","year":"2022","unstructured":"Ren K, Yang A, Lu J, Zhao D, Bai M, Ding J et al (2022) Association between serum low-density neutrophils and acute-onset and recurrent Guillain-Barr\u00e9 syndrome. Brain Behav 12(1):e2456. https:\/\/doi.org\/10.1002\/brb3.2456","journal-title":"Brain Behav"},{"issue":"11","key":"12321_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14(11):1103\u20131109. https:\/\/doi.org\/10.1002\/mus.880141111","journal-title":"Muscle Nerve"},{"issue":"3","key":"12321_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/jns.12118","volume":"20","author":"EK Vanhoutte","year":"2015","unstructured":"Vanhoutte EK, Draak TH, Gorson KC, van Nes SI, Hoeijmakers JG, Van der Pol WL et al (2015) Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison. J Peripher Nerv Syst: JPNS 20(3):289\u2013295. https:\/\/doi.org\/10.1111\/jns.12118","journal-title":"J Peripher Nerv Syst: JPNS"},{"issue":"12","key":"12321_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","volume":"5","author":"LJ Blumberg","year":"2019","unstructured":"Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A et al (2019) Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv 5(12):eaax9586. https:\/\/doi.org\/10.1126\/sciadv.aax9586","journal-title":"Sci Adv"},{"key":"12321_CR25","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540","journal-title":"Front Immunol"},{"issue":"4","key":"12321_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/cnd.0000000000000451","volume":"24","author":"M Jaffry","year":"2023","unstructured":"Jaffry M, Menkes DL, Shaikh A, Mandava K, Kothari O, Jaffry K et al (2023) Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease. J Clin Neuromuscul Dis 24(4):188\u2013198. https:\/\/doi.org\/10.1097\/cnd.0000000000000451","journal-title":"J Clin Neuromuscul Dis"},{"issue":"9","key":"12321_CR27","doi-asserted-by":"publisher","first-page":"Cd002063","DOI":"10.1002\/14651858.CD002063.pub6","volume":"2014","author":"RA Hughes","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2014(9):Cd002063. https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"12321_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mus.27414","volume":"64","author":"F Zhao","year":"2021","unstructured":"Zhao F, Wang J, Zhang J, Pang X, Huang S, Chang X et al (2021) Pain in acute motor axonal neuropathy. Muscle Nerve 64(6):739\u2013743. https:\/\/doi.org\/10.1002\/mus.27414","journal-title":"Muscle Nerve"},{"key":"12321_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","volume":"5","author":"KM Sand","year":"2014","unstructured":"Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2014) Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 5:682. https:\/\/doi.org\/10.3389\/fimmu.2014.00682","journal-title":"Front Immunol"},{"issue":"2","key":"12321_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","volume":"74","author":"WR Fokkink","year":"2017","unstructured":"Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC (2017) Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barr\u00e9 syndrome. JAMA Neurol 74(2):189\u2013196. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4480","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12321-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:14:06Z","timestamp":1716995646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12321-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["12321"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12321-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any financial and conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This report has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All the patients provided written informed consent according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}